Chronic Kidney Disease (CKD) Drugs Market Revenue, Growth, Developments, Size, Share and Forecast 20

Chronic Kidney Disease (CKD) Drugs Market was valued at USD 13.13 billion in 2023 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.6% from 2024 to 2030, reaching nearly USD 19.22 billion by 2030. ​

Overview

Chronic Kidney Disease (CKD) is a progressive condition characterized by the gradual loss of kidney function over time. It poses significant health challenges worldwide, with approximately 15% of adults in the United States—about 37 million individuals—affected by CKD. Globally, over 850 million people were estimated to have kidney disease in 2020, making it a substantial public health concern. CKD increases the risk of cardiovascular diseases, such as heart disease and stroke, and can lead to kidney failure if not managed effectively. ​

To Know More About This Report Request A Free Sample Copy: https://www.maximizemarketresearch.com/request-sample/39171/

Market Scope

The CKD Drugs Market encompasses a range of therapeutic classes aimed at managing the progression and complications of CKD. Key drivers influencing market growth include:​

• Rising Prevalence of CKD: An increase in risk factors such as diabetes, hypertension, and aging populations contributes to the growing incidence of CKD.​
• Advancements in Drug Development: Ongoing research and development efforts are leading to the introduction of novel therapies that improve patient outcomes.​
• Healthcare Infrastructure Improvements: Enhanced access to healthcare services and early diagnosis are facilitating better management of CKD.​

Segmentation

The CKD Drugs Market is segmented based on drug class, end user, and region:​

• By Drug Class:
• ACE Inhibitors
• Angiotensin-II Receptor Blockers (ARBs)
• Calcium Channel Blockers
• Beta Blockers
• Erythropoiesis-Stimulating Agents (ESAs)
• Diuretics
• Others​
• By End User:
• Hospitals
• Specialty Clinics
• Others​
• By Region:
• North America
• Europe
• Asia-Pacific
• Middle East & Africa
• South America​

Major Manufacturers

• AbbVie Inc. (US)
• Amgen Inc. (US)
• AstraZeneca Plc (UK)
• Bayer AG (Germany)
• Boehringer Ingelheim International GmbH (Germany)
• GlaxoSmithKline Plc (UK)
• Johnson & Johnson (US)
• Kissei Pharmaceutical Co., Ltd. (Japan)
• Pfizer Inc. (US)
• Teva Pharmaceutical Industries Ltd. (Israel)​

Regional Analysis

• United States: With approximately 15% of adults affected by CKD, the U.S. represents a significant market for CKD drugs. The high prevalence is driven by factors such as diabetes and hypertension. ​
• Germany: As a key player in the European pharmaceutical market, Germany contributes substantially to the CKD drugs market, supported by advanced healthcare infrastructure and a growing elderly population.​

COVID-19 Impact Analysis

The COVID-19 pandemic has had a multifaceted impact on the CKD drugs market. While disruptions in healthcare services affected routine CKD management, the heightened focus on comorbidities and chronic conditions has underscored the importance

Top of Form

Bottom of Form